Home The Word Brain	My Amedeo FAQ Privacy About
	2049 Chinese The 20K Word Road to Mandarin Proficiency By B. S. Kamps et al.

Leukemia

Free Subscription Articles published in Leuk Res Retrieve available abstracts of 253 articles: HTML format

Single Articles

April 2024
1. SMITH BD, Brummendorf TH, Roboz GJ, Gambacorti-Passerini C, et al
   Efficacy and safety of bosutinib in patients treated with prior imatinib and/or dasatinib and/or nilotinib: Subgroup analyses from the phase 4 BYOND study.
   Leuk Res. 2024;139:107481.
   PubMed     Abstract available
   
   
   
2. MORSY MM, Azzam AY, Elamin O, Elswedy A, et al
   Safety and efficacy of chimeric antigen receptor T-cell therapy for acute myeloid leukemia: A subgroup based meta-analysis.
   Leuk Res. 2024;140:107498.
   PubMed     Abstract available
   
   
   March 2024
3. YIGIT KAYA S, Mutlu YG, Malkan UY, Mehtap O, et al
   Single agent vemurafenib or rituximab-vemurafenib combination for the treatment of relapsed/refractory hairy cell leukemia, a multicenter experience.
   Leuk Res. 2024;140:107495.
   PubMed     Abstract available
   
   
   
4. MUTHIAH C, Narra R, Atallah E, Juan W, et al
   Evaluating population-level outcomes in Chronic Lymphocytic leukemia in the era of novel therapies using the SEER registry.
   Leuk Res. 2024;140:107496.
   PubMed     Abstract available
   
   
   
5. BRUNETTI M, Iasenza IA, Jenner AL, Raynal NJ, et al
   Mathematical modelling of clonal reduction therapeutic strategies in acute myeloid leukemia.
   Leuk Res. 2024;140:107485.
   PubMed     Abstract available
   
   
   
6. IKOMA-COLTURATO MRV, Severino AR, Dos Santos Tosi JF, Bertolucci CM, et al
   Clinical validation of a 10-color flow cytometry panel to detect measurable residual disease in acute myeloid leukemia.
   Leuk Res. 2024;140:107482.
   PubMed    
   
   
   
7. GARCIA-MANERO G, Kazmierczak M, Wierzbowska A, Fong CY, et al
   Pracinostat combined with azacitidine in newly diagnosed adult acute myeloid leukemia (AML) patients unfit for standard induction chemotherapy: PRIMULA phase III study.
   Leuk Res. 2024 Mar 12:107480. doi: 10.1016/j.leukres.2024.107480.
   PubMed     Abstract available
   
   
   
8. WAN CL, Huang YH, Huang SM, Xu YL, et al
   Investigations of the prognostic value of RUNX1 mutation in acute myeloid leukemia patients: Data from a real-world study.
   Leuk Res. 2024;139:107483.
   PubMed     Abstract available
   
   
   
9. PAN L, Li Y, Gao H, Lai X, et al
   Clinical features and management of germline CEBPA-mutated carriers.
   Leuk Res. 2024;138:107453.
   PubMed     Abstract available
   
   
   
10. SIDI Y, Dong C, Wu Y, Faller DV, et al
    A critical evaluation of the EFS endpoint in AML: Does induction treatment failure timing have a profound impact on study design and results?
    Leuk Res. 2024;138:107465.
    PubMed     Abstract available
    
    
    February 2024
11. BOURNE G, Diebold K, Espinoza-Gutarra M, Al-Kadhimi Z, et al
    Addition of single dose gemtuzumab ozogamicin to intensive induction chemotherapy in core-binding factor acute myeloid leukemia.
    Leuk Res. 2024;139:107467.
    PubMed     Abstract available
    
    
    
12. ZHONG S, Kurish H, Walchack R, Li H, et al
    Efficacy and safety of mitoxantrone, etoposide, and cytarabine for treatment of relapsed or refractory acute myeloid leukemia.
    Leuk Res. 2024;139:107468.
    PubMed     Abstract available
    
    
    
13. OSMAN AEG, Rets A, Patel AB
    KRAS mutations, autoimmunity and female sex in chronic myelomonocytic leukemia.
    Leuk Res. 2024;138:107466.
    PubMed    
    
    
    
14. SANCHEZ-PETITTO G, Goloubeva OG, Masur J, Childress J, et al
    Clinical outcomes of patients with acute myeloid leukemia and cardiovascular disease.
    Leuk Res. 2024;138:107456.
    PubMed     Abstract available
    
    
    
15. SUDO H, Tonoyama Y, Ikebe E, Hasegawa H, et al
    Proteomic analysis of adult T-cell leukemia/lymphoma: A biomarker identification strategy based on preparation and in-solution digestion methods of total proteins.
    Leuk Res. 2024;138:107454.
    PubMed     Abstract available
    
    
    
16. GOULART H, Sastow D, Moshier E, Martin L, et al
    Systematic review and meta-analysis evaluating clinical outcomes in adult acute myeloid leukemia patients with central nervous system involvement.
    Leuk Res. 2024;137:107452.
    PubMed     Abstract available
    
    
    
17. ELGHETANY MT, Patnaik MM, Khoury JD
    Myelodysplastic neoplasms evolving from inherited bone marrow failure syndromes / germline predisposition syndromes: Back under the microscope.
    Leuk Res. 2024;137:107441.
    PubMed     Abstract available
    
    
    
18. RAMOS-CILLAN S, Lainez-Gonzalez D, Solan L, Blas C, et al
    When the devil is in the details: Similarities and differences between WHO and ICC classifications of AML.
    Leuk Res. 2024;137:107440.
    PubMed    
    
    
    January 2024
19. BOUCHER L, Rozalska L, Sorel N, Olivier G, et al
    Emergence of secondary fusions in chronic myeloid leukemia as a driver of tyrosine kinase inhibitor resistance and blast crisis transformation.
    Leuk Res. 2024;137:107439.
    PubMed    
    
    
    
20. OH I, Hatano K, Ikeda T, Toda Y, et al
    Phase 2 trial of induction with dasatinib and consolidation with hyper-CVAD plus dasatinib followed by allografting for Ph-positive acute lymphoblastic leukemia in adults.
    Leuk Res. 2024;137:107438.
    PubMed    
    
    
    
21. DIDI I, Alliot JM, Dumas PY, Vergez F, et al
    Artificial intelligence-based prediction models for acute myeloid leukemia using real-life data: A DATAML registry study.
    Leuk Res. 2024;136:107437.
    PubMed     Abstract available
    
    
    
22. KLINK AJ, Gajra A, Knoth RL, Marshall L, et al
    Corrigendum to "Real-world clinical outcomes with enasidenib in relapsed or refractory acute myeloid leukemia" [Leuk. Res. (2022) 106946].
    Leuk Res. 2024 Jan 9:107430. doi: 10.1016/j.leukres.2023.107430.
    PubMed    
    
    
    
23. KUSNE Y, Lasho T, Finke C, Patnaik MM, et al
    VEXAS syndrome in a patient with DDX41 germline predisposition syndrome.
    Leuk Res. 2024;136:107432.
    PubMed    
    
    
    
24. KHANNA V, Lu R, Kumar J, Molina A, et al
    The clinical, molecular, and prognostic features of the 2022 WHO and ICC classification systems for myelodysplastic neoplasms.
    Leuk Res. 2024;136:107433.
    PubMed     Abstract available
    
    
    December 2023
25. NOTARANTONIO AB, Roth-Guepin G, Bonmati C, Divoux M, et al
    A new sequential conditioning regimen based on CPX- 351/Vyxeos ("Vyx-Seq") in patients with higher risk myelodysplastic syndromes.
    Leuk Res. 2023;135:107405.
    PubMed    
    
    
    November 2023
26. ASHBY M, Fleming S, Teh TC, Tiong IS, et al
    Low-intensity venetoclax-based salvage as a bridge to allogeneic stem cell transplant in patients with acute myeloid leukemia failing conventional intensive chemotherapy.
    Leuk Res. 2023;136:107429.
    PubMed    
    
    
    
27. URBINO I, Secreto C, Apolito V, Olivi M, et al
    Sorafenib in combination with intensive chemotherapy for relapsed or refractory FLT3-ITD positive acute myeloid leukemia: A two centers experience.
    Leuk Res. 2023 Nov 18:107421. doi: 10.1016/j.leukres.2023.107421.
    PubMed    
    
    
    
28. ZHAO D, Zhou Q, Zarif M, Eladl E, et al
    AML with CEBPA mutations: A comparison of ICC and WHO-HAEM5 criteria in patients with 20% or more blasts.
    Leuk Res. 2023;134:107376.
    PubMed     Abstract available
    
    
    October 2023
29. RAVINDRA A, Acharya L, Loeffler B, Mott S, et al
    Venetoclax-based therapy in treatment-naive and relapsed/refractory acute myeloid leukemia.
    Leuk Res. 2023;135:107407.
    PubMed     Abstract available
    
    
    
30. ANSARI F, Behfar M, Jafari L, Mohseni R, et al
    A comprehensive comparison between TBI vs non-TBI-based conditioning regimen in pediatric patients with acute lymphoblastic leukemia: A systematic review and meta-analysis.
    Leuk Res. 2023;135:107416.
    PubMed     Abstract available
    
    
    
31. ZHANG F, Du H, Hu C, Song Y, et al
    A new prognostic risk model for acute myeloid leukemia patients based on telomere-related genes.
    Leuk Res. 2023;135:107404.
    PubMed     Abstract available
    
    
    
32. SHERBAN A, Fredman D, Shimony S, Yeshurun M, et al
    Safety and efficacy of FLAG-Ida-based therapy combined with venetoclax for the treatment for newly diagnosed and relapsed/refractory patients with AML - A systematic review.
    Leuk Res. 2023;133:107368.
    PubMed     Abstract available
    
    
    September 2023
33. JIMENEZ-VICENTE C, Martinez-Roca A, Pomares H, Castano-Diez S, et al
    Venetoclax with hypomethylating agents might lead to eradication of measurable residual disease (MRD) persisting after intensive chemotherapy in acute myeloid leukemia (AML) patients with mutated NPM1 and rearranged CBF.
    Leuk Res. 2023;135:107403.
    PubMed    
    
    
    
34. JAMY OH, Kasner M, Wall S, Ingram S, et al
    Integrating electronic geriatric assessment and frailty screening for adults with acute myeloid leukemia to drive personalized treatment decisions.
    Leuk Res. 2023;134:107393.
    PubMed     Abstract available
    
    
    
35. GURNEY M, Greipp PT, Gliem T, Knudson R, et al
    TET2 somatic copy number alterations and allelic imbalances in chronic myelomonocytic leukemia.
    Leuk Res. 2023;134:107391.
    PubMed    
    
    
    
36. SINGH C, Karunakaran P, Yanamandra U, Jindal N, et al
    Factors associated with thrombo-hemorrhagic deaths in patients with Acute Promyelocytic leukemia treated with Arsenic Trioxide and all-trans retinoic acid.
    Leuk Res. 2023;134:107392.
    PubMed     Abstract available
    
    
    
37. PATEL SA, Bello E, Wilks A, Gerber JM, et al
    Harnessing autologous immune effector mechanisms in acute myeloid leukemia: 2023 update of trials and tribulations.
    Leuk Res. 2023;134:107388.
    PubMed     Abstract available
    
    
    
38. HIRT CK, Padmanabha N, Michaels PD
    Cohesin complex mutations in myeloid neoplasms are enriched for SRSF2, RUNX1, TET2, and NRAS co-mutations and morphologic dysplasia.
    Leuk Res. 2023;132:107357.
    PubMed    
    
    
    
39. BRANDWEIN JM, Ebeling K, Ding L, Liew E, et al
    Changing frontline AML treatment patterns from 2013 to 2022.
    Leuk Res. 2023;132:107354.
    PubMed     Abstract available
    
    
    
40. XIE W, Wang Z, Guo X, Guan H, et al
    MiR-409-3p regulates the proliferation and apoptosis of THP-1 through targeting Rab10.
    Leuk Res. 2023;132:107350.
    PubMed     Abstract available
    
    
    August 2023
41. DE LA GARZA-SALAZAR F, Colunga-Pedraza PR, Gomez-Almaguer D, Garcia-Zarate VA, et al
    Low dose venetoclax plus itraconazole outpatient induction in newly diagnosed acute myeloid leukemia: A phase 2 study.
    Leuk Res. 2023;133:107373.
    PubMed     Abstract available
    
    
    
42. KHADADAH FM, Cerquozzi S, Olney HJ, Fraga C, et al
    Canadian real-world experience of asciminib treatment in heavily pre-treated chronic myeloid leukemia (CML) patients who failed multiple lines of tyrosine kinase inhibitor (TKI) therapy.
    Leuk Res. 2023;133:107374.
    PubMed     Abstract available
    
    
    
43. OWEN C, Eisinga S, Banerji V, Johnson N, et al
    Canadian evidence-based guideline for treatment of relapsed/refractory chronic lymphocytic leukemia.
    Leuk Res. 2023;133:107372.
    PubMed     Abstract available
    
    
    
44. BOULIGNY IM, Murray G, Ho T, Doyel M, et al
    Abbreviated venetoclax with decitabine or azacitidine in acute myeloid leukemia.
    Leuk Res. 2023;134:107370.
    PubMed    
    
    
    
45. ZHAO ZY, Tang N, Lin LE
    A rare BCR-ABL1 transcript in chronic myeloid leukemia: Case report and literature review.
    Leuk Res. 2023;133:107369.
    PubMed     Abstract available
    
    
    
46. BHATTACHARJEE U, Jandial A, Singh C, Lekshmon KS, et al
    Pregnancy and long-term outcomes of female patients with chronic myeloid leukemia on tyrosine kinase inhibitors who experienced unplanned pregnancies.
    Leuk Res. 2023;133:107367.
    PubMed     Abstract available
    
    
    
47. JAIN T, Ware AD, Dalton WB, Pasca S, et al
    Co-occurring mutations in ASXL1, SRSF2, and SETBP1 define a subset of myelodysplastic/ myeloproliferative neoplasm with neutrophilia.
    Leuk Res. 2023;131:107345.
    PubMed     Abstract available
    
    
    
48. HASSAN HT
    Antibody-drug conjugate [ADC] treatment of leukaemia.
    Leuk Res. 2023;131:107078.
    PubMed     Abstract available
    
    
    July 2023
49. STAHL M, Giblin G, Liu Y, Winer ES, et al
    Incidence and predictors of anthracycline-related left ventricular dysfunction in acute myeloid leukemia.
    Leuk Res. 2023;132:107351.
    PubMed     Abstract available
    
    
    
50. BRUNNER AM, Huggar D, Copher R, Zhou ZY, et al
    Economic burden during remission and after relapse among older patients with newly diagnosed acute myeloid leukemia without hematopoietic stem cell transplant: A retrospective study using the SEER-Medicare database.
    Leuk Res. 2023;132:107353.
    PubMed     Abstract available
    
    
    
51. HEGER JM, Boll B, Naendrup JH, Simon F, et al
    Hyperleukocytosis in patients with acute myeloid leukemia admitted to the intensive care unit: a single-center retrospective analysis.
    Leuk Res. 2023;132:107352.
    PubMed     Abstract available
    
    
    
52. DENG X, Zeng Y, Qiu X, Zhong M, et al
    CRIP1 supports the growth and migration of AML-M5 subtype cells by activating Wnt/beta-catenin pathway.
    Leuk Res. 2023;130:107312.
    PubMed     Abstract available
    
    
    
53. KIRTEK T, Chen W, Laczko D, Bagg A, et al
    Acute leukemias with complex karyotype show a similarly poor outcome independent of mixed, myeloid or lymphoblastic immunophenotype: A study from the Bone Marrow Pathology Group.
    Leuk Res. 2023;130:107309.
    PubMed     Abstract available
    
    
    June 2023
54. RATAJCZAK B, Przybylowicz-Chalecka A, Czerwinska-Rybak J, Kandula Z, et al
    The presence of additional cytogenetic aberrations in chronic myeloid leukemia cells at the time of diagnosis or their appearance on tyrosine kinase inhibitor therapy predicts the imatinib treatment failure.
    Leuk Res. 2023;132:107349.
    PubMed     Abstract available
    
    
    
55. SHAIKH MR, Singh B, Halder R, Singh R, et al
    FLAG based v/s Standard 3 + 7 induction therapy in treatment naive Acute Myeloid Leukemia: Time to think "beyond anthracyclines".
    Leuk Res. 2023;132:107346.
    PubMed     Abstract available
    
    
    
56. GUARANA M, Nucci M
    Should patients with acute myeloid leukemia treated with venetoclax-based regimens receive antifungal prophylaxis?
    Leuk Res. 2023;131:107341.
    PubMed     Abstract available
    
    
    
57. MOORE JE, Bloom PC, Chu CC, Bruno JE, et al
    Rituximab induced cytokine release with high serum IP-10 (CXCL10) concentrations is associated with infusion reactions.
    Leuk Res. 2023;129:107072.
    PubMed     Abstract available
    
    
    May 2023
58. KHANNA V, Azenkot T, Liu SQ, Gilbert J, et al
    Outcomes with molecularly targeted agents as salvage therapy following frontline venetoclax + hypomethylating agent in adults with acute myeloid leukemia: A multicenter retrospective analysis.
    Leuk Res. 2023;131:107331.
    PubMed    
    
    
    
59. ILLANGESWARAN RSS, Jebanesan DZP, Sivakumar KK, Vidhyadharan RT, et al
    Corrigendum to "Chemotherapeutic drugs elicit stemness and metabolic alteration to mediate acquired drug-resistant phenotype in acute myeloid leukemia cell lines" [Leukemia Res. 128, 107054].
    Leuk Res. 2023 May 29:107329. doi: 10.1016/j.leukres.2023.107329.
    PubMed    
    
    
    
60. BADE R, Banaszak LG, Osman F, Cabral P, et al
    Neighborhood disadvantage, insurance status, and molecular profiling of patients with acute myeloid leukemia.
    Leuk Res. 2023;131:107326.
    PubMed     Abstract available
    
    
    
61. MARTINEZ-CASTILLO M, Gomez-Romero L, Tovar H, Olarte-Carrillo I, et al
    Genetic alterations in the BCR-ABL1 fusion gene related to imatinib resistance in chronic myeloid leukemia.
    Leuk Res. 2023;131:107325.
    PubMed     Abstract available
    
    
    
62. SALAMA H, Eldadah S, Omer MH, Alhejazi A, et al
    Comparison of a modified pediatric protocol versus a hyper-CVAD protocol in adolescents and young adults with Philadelphia-negative acute lymphoblastic leukemia: A multicenter retrospective analysis.
    Leuk Res. 2023;130:107316.
    PubMed     Abstract available
    
    
    
63. WU X, Thisdelle J, Hou S, Fajardo-Despaigne JE, et al
    Elevated expression of interleukin 16 in chronic lymphocytic leukemia is associated with disease burden and abnormal immune microenvironment.
    Leuk Res. 2023;131:107315.
    PubMed     Abstract available
    
    
    
64. OYA S, Ozawa H, Maehiro Y, Nakamura T, et al
    Alternating venetoclax/azacytidine and FLT3 inhibitor treatment for NPM1- and FLT3-mutated acute myeloid leukemia.
    Leuk Res. 2023;130:107313.
    PubMed    
    
    
    
65. ATCHLEY E, Weis TM, Derkach A, Galera PK, et al
    Outcomes with high dose cytarabine and mitoxantrone induction for adults with mixed phenotype acute leukemia.
    Leuk Res. 2023;130:107311.
    PubMed     Abstract available
    
    
    
66. WANG Y, Liu H, Wang H, Wu Y, et al
    Enhancing morphological analysis of peripheral blood cells in chronic lymphocytic leukemia with an artificial intelligence-based tool.
    Leuk Res. 2023;130:107310.
    PubMed     Abstract available
    
    
    
67. BALSAT M, Alcazer V, Etienne G, Huguet F, et al
    First-line second generation tyrosine kinase inhibitors in patients with newly diagnosed accelerated phase chronic myeloid leukemia.
    Leuk Res. 2023;130:107308.
    PubMed     Abstract available
    
    
    
68. EDMUND J, Thaliath LJ, Meleveedu K
    Acute myeloid leukemia in the medically unfit elderly patients.
    Leuk Res. 2023;130:107306.
    PubMed     Abstract available
    
    
    
69. ARCHIBALD WJ, Baran AM, Williams AM, Salloum RM, et al
    The role of splenectomy in management of splenic B-cell lymphomas.
    Leuk Res. 2023;128:107053.
    PubMed     Abstract available
    
    
    
70. SUN X, Bai Y, Li M, Li W, et al
    Differential effects of recombinant human thrombopoietin on clinical outcomes in CD7-positive and CD7-negative acute myeloid leukaemia.
    Leuk Res. 2023;128:107034.
    PubMed     Abstract available
    
    
    April 2023
71. TINAJERO J, Koller P, Ali H
    Ponatinib, asciminib and inotuzumab ozogamicin: A novel drug combination in acute lymphoblastic leukemia.
    Leuk Res. 2023;129:107299.
    PubMed    
    
    
    
72. AIMAN W, Ali MA, Basit MA, Omar Z, et al
    Efficacy and tolerability of isocitrate dehydrogenase inhibitors in patients with acute myeloid leukemia: A systematic review of clinical trials.
    Leuk Res. 2023;129:107077.
    PubMed     Abstract available
    
    
    
73. WILDE L, Porazzi P, Trotta R, De Dominici M, et al
    A phase I study of the combination of palbociclib and dexamethasone for the treatment of relapsed or refractory B-cell acute lymphoblastic leukemia.
    Leuk Res. 2023;129:107075.
    PubMed     Abstract available
    
    
    
74. OWEN C, Banerji V, Johnson N, Gerrie A, et al
    Corrigendum to "Canadian evidence-based guideline for frontline treatment of chronic lymphocytic leukemia: 2022 update" [Leukemia Research 125 (2023) 107016].
    Leuk Res. 2023 Apr 3:107073. doi: 10.1016/j.leukres.2023.107073.
    PubMed    
    
    
    
75. JINDRA P, Karas M, Lysak D, Sramek J, et al
    Determinants of refined GvHD-free, relapse-free survival after reduced-intensity allogeneic hematopoietic cell transplantation in older patients with myeloid malignancies.
    Leuk Res. 2023;127:107052.
    PubMed     Abstract available
    
    
    
76. MIRET M, Anderson A, Hindocha P, Cirneanu L, et al
    Incidence of second primary malignancies in relapsed/refractory B-cell non-Hodgkin's lymphoma patients in England.
    Leuk Res. 2023;127:107042.
    PubMed     Abstract available
    
    
    
77. KIRKIZLAR TA, Kirkizlar O, Demirci U, Umut A, et al
    Incidence and predisposing factors of infection in patients treated with hypomethylating agents.
    Leuk Res. 2023;127:107043.
    PubMed     Abstract available
    
    
    March 2023
78. YI ES, Baek HJ, Ju HY, Kim SK, et al
    Response to chemotherapy in juvenile myelomonocytic leukemia and its clinical implications for survival: A retrospective registry-based study of the Korean Pediatric Hematology-Oncology Group.
    Leuk Res. 2023;129:107070.
    PubMed     Abstract available
    
    
    
79. DELIA M, Gagliardi VP, Carluccio P, Attolico I, et al
    Long term follow-up of refractory/relapsed acute myeloid leukemia patients treated with the FLAG-Ida regimen as bridge therapy to allotransplantation: 10-year results from a single centre experience.
    Leuk Res. 2023;129:107069.
    PubMed    
    
    
    
80. CHEN S, Tao Y, Wang Q, Ren J, et al
    Glucose induced-AKT/mTOR activation accelerates glycolysis and promotes cell survival in acute myeloid leukemia.
    Leuk Res. 2023;128:107059.
    PubMed     Abstract available
    
    
    
81. CHANTEPIE SP, Mear JB, Briant AR, Vilque JP, et al
    Effect of single-unit transfusion in patients treated for haematological disease including acute leukemia: A multicenter randomized controlled clinical trial.
    Leuk Res. 2023;129:107058.
    PubMed     Abstract available
    
    
    
82. ILLANGESWARAN RSS, Jebanesan DZP, Sivakumar KK, Vidhyadharan RT, et al
    Chemotherapeutic drugs elicit stemness and metabolic alteration to mediate acquired drug-resistant phenotype in acute myeloid leukemia cell lines.
    Leuk Res. 2023;128:107054.
    PubMed     Abstract available
    
    
    
83. KILIC GUNES E, Ozkurt ZN, Yildiz S, Ozet G, et al
    Comparison of maintenance regimens in Acute Promyelocytic Leukemia patients.
    Leuk Res. 2023;128:107055.
    PubMed     Abstract available
    
    
    
84. LAPIETRA G, Limongi MZ, Buffolino S, Nanni M, et al
    Late appearance of JAK2 mutated polycythaemia vera in a patient with typical chronic myeloid leukaemia on imatinib: Speculations about role of therapeutic pressure and of secondary genetic events.
    Leuk Res. 2023;126:107035.
    PubMed    
    
    
    
85. JAHN J, Diamond B, Hsu J, Montoya S, et al
    Therapy-selected clonal hematopoiesis and its role in myeloid neoplasms.
    Leuk Res. 2023;126:107020.
    PubMed     Abstract available
    
    
    February 2023
86. BATALLER A, Chien KS, Sasaki K, Montalban-Bravo G, et al
    PHF6 mutations in myelodysplastic syndromes, chronic myelomonocytic leukemia and acute myeloid leukemia.
    Leuk Res. 2023;127:107044.
    PubMed    
    
    
    
87. MAURILLO L, Spagnoli A, Candoni A, Papayannidis C, et al
    Comparison between azacitidine and decitabine as front-line therapy in elderly acute myeloid leukemia patients not eligible for intensive chemotherapy.
    Leuk Res. 2023;127:107040.
    PubMed     Abstract available
    
    
    
88. YANG Z, Liu C, Hu Y, Liu H, et al
    Tyrosine kinase inhibitors combined with venetoclax and azacytidine as an effective therapy for de novo lymphoid blast phase-chronic myeloid leukemia.
    Leuk Res. 2023;127:107039.
    PubMed    
    
    
    
89. PREMNATH N, Chung SS, Weinberg OK, Ikpefan R, et al
    Clinical and molecular characteristics associated with Vitamin C deficiency in myeloid malignancies; real world data from a prospective cohort.
    Leuk Res. 2023;125:107001.
    PubMed     Abstract available
    
    
    January 2023
90. TARANTINI F, Cumbo C, Zagaria A, Anelli L, et al
    Clonal hematopoiesis onset in chronic myeloid leukemia patients developing an adverse cardiovascular event.
    Leuk Res. 2023;127:107023.
    PubMed     Abstract available
    
    
    
91. MOHAMMADI F, Rostami G, Hamid M, Shafiei M, et al
    Association of ABCB1, ABCG2 drug transporter polymorphisms and smoking with disease risk and cytogenetic response to imatinib in chronic myeloid leukemia patients.
    Leuk Res. 2023;126:107021.
    PubMed     Abstract available
    
    
    
92. NABIL R, Abdellateif MS, Gamal H, Hassan NM, et al
    Clinical significance of EVI-1 gene expression and aberrations in patient with de-novo acute myeloid and acute lymphoid leukemia.
    Leuk Res. 2023;126:107019.
    PubMed     Abstract available
    
    
    
93. OWEN C, Banerji V, Johnson N, Gerrie A, et al
    Canadian evidence-based guideline for frontline treatment of chronic lymphocytic leukemia: 2022 update.
    Leuk Res. 2023;125:107016.
    PubMed     Abstract available
    
    
    
94. HEEKUK P, Uhlemann AC, Jacobs SS, Mowbray C, et al
    Title: Obesogenic microbial signatures and the development of obesity in childhood acute lymphoblastic leukemia.
    Leuk Res. 2023;126:107017.
    PubMed     Abstract available
    
    
    
95. DEMINA I, Zerkalenkova E, Semchenkova A, Volchkov E, et al
    Rare case of pediatric trilineal mixed-phenotype acute leukemia with t(11;19)(q23.3;p13)/KMT2A::ELL.
    Leuk Res. 2023;125:107018.
    PubMed    
    
    
    
96. FUKUDA S, Matsuda N, Shoji T, Onishi C, et al
    The magnitude of CXCR4 signaling regulates resistance to quizartinib in FLT3/ITD(+) cells via RUNX1.
    Leuk Res. 2023;124:106983.
    PubMed     Abstract available
    
    
    
97. RAMANAN R, Tiong IS, Ivey A, Ong DM, et al
    Cellular distribution of IDH mutations in AML during morphologic remission.
    Leuk Res. 2023;124:106993.
    PubMed     Abstract available
    
    
    December 2022
98. RAMAN HS, Kim SE, DeAngelo DJ, Stevenson KE, et al
    Intensity of induction regimen and outcomes among adults with Ph+ALL undergoing allogeneic hematopoietic stem cell transplantation.
    Leuk Res. 2022;125:107004.
    PubMed     Abstract available
    
    
    
99. POPOV A, Henze G, Roumiantseva J, Budanov O, et al
    Flow cytometric MRD at the end of consolidation in childhood B-lineage acute lymphoblastic leukemia has significant prognostic value but limited clinical implications: Results of study ALL-MB 2008.
    Leuk Res. 2022;125:106998.
    PubMed    
    
    
    
100. ZHOU Q, Zhao D, Eladl E, Capo-Chichi JM, et al
     Molecular genetic characterization of Philadelphia chromosome-positive acute myeloid leukemia.
     Leuk Res. 2022;124:107002.
     PubMed     Abstract available
     
     
     
101. ABEDIN SM, Badar T, Gauger K, Michaelis LC, et al
     Safety and efficacy of pracinostat in combination with gemtuzumab ozogamicin (PraGO) in patients with relapsed/refractory acute myeloid leukemia.
     Leuk Res. 2022;123:106984.
     PubMed    
     
     
     
102. RAMIA DE CAP M, Wu LP, Pihan GA, Narayanan D, et al
     NPM1 mutations may be associated with adverse outcome in the setting of myeloid neoplasms with complex karyotype.
     Leuk Res. 2022;123:106965.
     PubMed    
     
     
     
103. GABRA MM, Chow JT, Kim T, Son MH, et al
     A 5-microRNA signature derived from core binding factor-AML is predictive in adult and childhood AML.
     Leuk Res. 2022;123:106968.
     PubMed    
     
     
     November 2022
104. COTTINGHAM AH, Baker LB, Hoffmann ML, Martin CE, et al
     We were in the fight together: The expectations of bereaved caregivers of patients with acute myeloid leukemia from diagnosis to death.
     Leuk Res. 2022;124:106994.
     PubMed     Abstract available
     
     
     
105. OERTLING E, Fuda F, Koduru P, Chen M, et al
     Distinct mutational and clinicopathologic profiles characterize acute myeloid leukemia with cup-like nuclei.
     Leuk Res. 2022;124:106995.
     PubMed    
     
     
     
106. KING AC, Derkach A, Weis TM, Stump SE, et al
     Real-world analysis of the safety/tolerability of gilteritinib in combination with mold-active azole prophylaxis.
     Leuk Res. 2022;122:106929.
     PubMed    
     
     
     October 2022
107. POPOV A, Henze G, Roumiantseva J, Budanov O, et al
     A single flow cytometric MRD measurement in children with B-lineage acute lymphocytic leukemia and hyperleukocytosis redefines the requirements of high-risk treatment: Results of the study ALL-MB 2008.
     Leuk Res. 2022;123:106982.
     PubMed    
     
     
     
108. PARISI R, Cowen EA, Stoll JR, Zhu H, et al
     Dermatologic adverse events associated with IDH inhibitors ivosidenib and enasidenib for the treatment of acute myeloid leukemia.
     Leuk Res. 2022;123:106970.
     PubMed     Abstract available
     
     
     
109. KAYA Z, Keser E, Atalay E, Kayhan G, et al
     Two distinct syndromic children with T-acute lymphoblastic leukemia: Noonan syndrome and Sotos syndrome.
     Leuk Res. 2022;123:106981.
     PubMed    
     
     
     
110. GANZEL C, Sun Z, Baslan T, Zhang Y, et al
     Measurable residual disease by flow cytometry in acute myeloid leukemia is prognostic, independent of genomic profiling.
     Leuk Res. 2022;123:106971.
     PubMed     Abstract available
     
     
     
111. FUJIWARA SI, Murahashi R, Nakashima H, Matsuoka S, et al
     Effect of cumulative daunorubicin dose on cardiotoxicity after allogeneic stem cell transplantation.
     Leuk Res. 2022;121:106951.
     PubMed     Abstract available
     
     
     
112. LI L, Hu X, Nkwocha J, Sharma K, et al
     Functional role of DNMT1 in the anti-leukemic effects of hypomethylating agents in AML cells.
     Leuk Res. 2022;121:106944.
     PubMed    
     
     
     
113. NANAA A, He R, Viswanatha D, Nguyen P, et al
     Comparison between GATA2 and DDX41-mutated myeloid neoplasms.
     Leuk Res. 2022;121:106931.
     PubMed    
     
     
     
114. PODGORNIK H, Sucurovic S, Skerget M, Debeljak M, et al
     Acquired somatic variants confirm the independent development of AML in monozygotic twins with germline CEBPA variant.
     Leuk Res. 2022;121:106933.
     PubMed    
     
     
     
115. RAINCHWAR S, Halder R, Singh R, Mehta P, et al
     Pneumocystis jirovecii pneumonia [PJP]: An unrecognized concern in AML patients on Venetoclax.
     Leuk Res. 2022;121:106926.
     PubMed     Abstract available
     
     
     September 2022
116. DEFINA M, Lazzarotto D, Guolo F, Minetto P, et al
     Levocarnitine supplementation for asparaginase-induced hepatotoxicity in adult acute lymphoblastic leukemia patients: A multicenter observational study of the campus all group.
     Leuk Res. 2022;122:106963.
     PubMed    
     
     
     
117. MEENA JP, Pathak N, Gupta AK, Bakhshi S, et al
     Molecular evaluation of gene mutation profiles and copy number variations in pediatric acute myeloid leukemia.
     Leuk Res. 2022;122:106954.
     PubMed     Abstract available
     
     
     
118. LAN X, Ruminy P, Bohers E, Rainville V, et al
     5' Rapid amplification of cDNA ends (5'RACE): A simpler method to analyze immunoglobulin genes and discover the value of the light chain in chronic lymphocytic leukemia.
     Leuk Res. 2022;123:106952.
     PubMed     Abstract available
     
     
     
119. MA S, Rosen ST, Winqvist M, Frankfurt O, et al
     Dual targeting fixed duration frontline monoclonal antibody therapy for chronic lymphocytic leukemia: A phase 2 study.
     Leuk Res. 2022;122:106945.
     PubMed     Abstract available
     
     
     
120. KLINK AJ, Gajra A, Knoth RL, Marshall L, et al
     Real-world clinical outcomes with enasidenib in relapsed or refractory acute myeloid leukemia.
     Leuk Res. 2022;122:106946.
     PubMed     Abstract available
     
     
     
121. ANGHELINA M, Naughton MJ, Zhao Q, Ruppert AS, et al
     Corrigendum to "Patient-driven research: Initial results from a prospective health-related quality of life study performed at the request of patients living with hairy cell leukemia" [Leuk. Res. 120 (2022) 106919].
     Leuk Res. 2022 Sep 2:106943. doi: 10.1016/j.leukres.2022.106943.
     PubMed    
     
     
     
122. QI K, Hu X, Yu X, Cheng H, et al
     Targeting cyclin-dependent kinases 4/6 inhibits survival of megakaryoblasts in acute megakaryoblastic leukaemia.
     Leuk Res. 2022;120:106920.
     PubMed     Abstract available
     
     
     August 2022
123. BEWERSDORF JP, Shallis RM, Derkach A, Goldberg AD, et al
     Efficacy of FLT3 and IDH1/2 inhibitors in patients with acute myeloid leukemia previously treated with venetoclax.
     Leuk Res. 2022;122:106942.
     PubMed     Abstract available
     
     
     
124. GARCIA-VILLASENOR E, Cortes JE, Reyes-Cisneros OA, Fernandez-Gutierrez JA, et al
     Long-term results of the treatment of adolescents and adults with acute lymphoblastic leukemia with a pediatric-inspired regimen delivered on an outpatient basis: A single institution experience.
     Leuk Res. 2022;121:106935.
     PubMed     Abstract available
     
     
     
125. CHEN H, Xu LP, Zhang XH, Wang Y, et al
     Safety and outcomes of maintenance therapy with third-generation tyrosine kinase inhibitor after allogeneic hematopoietic cell transplantation in Philadelphia chromosome positive acute lymphoblastic leukemia patients with T315I mutation.
     Leuk Res. 2022;121:106930.
     PubMed     Abstract available
     
     
     
126. DHAKAL P, Lyden E, Joshi U, Pyakuryal A, et al
     Charlson comorbidity index predicts early mortality and overall survival in acute promyelocytic leukemia.
     Leuk Res. 2022;122:106927.
     PubMed    
     
     
     
127. ORTI G, Garcia-Gutierrez V, Bautista G, Ferrer-Marin F, et al
     Tyrosine kinase inhibitor dose reduction during the management ofaccelerated phase chronic myeloid leukemia.
     Leuk Res. 2022;121:106923.
     PubMed    
     
     
     
128. MARLEY AR, Ryder JR, Turcotte LM, Spector LG, et al
     Maternal obesity and acute lymphoblastic leukemia risk in offspring: A summary of trends, epidemiological evidence, and possible biological mechanisms.
     Leuk Res. 2022;121:106924.
     PubMed     Abstract available
     
     
     
129. KOLODRUBIEC J, Kozlowska M, Irga-Jaworska N, Sedek L, et al
     Efficacy of ruxolitinib in acute lymphoblastic leukemia: A systematic review.
     Leuk Res. 2022;121:106925.
     PubMed     Abstract available
     
     
     July 2022
130. ANGHELINA M, Naughton MJ, Zhao Q, Ruppert AS, et al
     Patient-driven research: Initial results from a prospective health-related quality of life study performed at the request of patients living with hairy cell leukemia.
     Leuk Res. 2022;120:106919.
     PubMed     Abstract available
     
     
     
131. BARKHORDAR M, Kasaeian A, Janbabai G, Mousavi SA, et al
     Outcomes of haploidentical peripheral stem cell transplantation with combination of post-transplant cyclophosphamide (PTCy) and anti-thymocyte globulin (ATG) compared to unrelated donor transplantation in acute myeloid leukemia: A retrospective 10-yea
     Leuk Res. 2022;120:106918.
     PubMed     Abstract available
     
     
     
132. ZHAO D, Zarif M, Eladl E, Capo-Chichi JM, et al
     NPM1-mutated AML-MRC diagnosed on the basis of history of MDS or MDS/MPN frequently harbours secondary-type mutations and confers inferior outcome compared to AML with mutated NPM1.
     Leuk Res. 2022;118:106869.
     PubMed     Abstract available
     
     
     
133. CHAUVET P, Nibourel O, Berthon C, Goursaud L, et al
     Resurgence of myeloproliferative neoplasm in patients in remission from blast transformation after treatment with hypomethylating agents.
     Leuk Res. 2022;118:106871.
     PubMed     Abstract available
     
     
     
134. LIU J, Qin W, Wang B, Wang Z, et al
     PTPN11 mutations in adult acute myeloid leukaemia: Prevalence and clinical implications in the context of NPM1 mutation.
     Leuk Res. 2022;118:106859.
     PubMed     Abstract available
     
     
     June 2022
135. LIPILKIN PV, Kulaeva ED, Mashkina EV
     Prognostic value of ASXL1 mutations in acute myeloid leukemia: A meta-analysis.
     Leuk Res. 2022;120:106910.
     PubMed     Abstract available
     
     
     
136. GAO X, Fan S, Zhang X
     MiR-1306-5p promotes cell proliferation and inhibits cell apoptosis in acute myeloid leukemia by downregulating PHF6 expression.
     Leuk Res. 2022;120:106906.
     PubMed     Abstract available
     
     
     
137. CHOJECKI AL, Arnall J, Boselli D, Patel R, et al
     Outcomes and hospitalization patterns of patients with acute myelogenous leukemia treated with frontline CPX-351 or HMA/venetoclax.
     Leuk Res. 2022;119:106904.
     PubMed    
     
     
     
138. DUMAS PY, Bertoli S, Bonmati C, Carre M, et al
     Characteristics and clinical outcomes of SARS-CoV-2 infection in adult patients with acute leukemia in France.
     Leuk Res. 2022;120:106901.
     PubMed    
     
     
     
139. FRISCH A, Aumann S, Zuckerman T, Leiba R, et al
     Re-induction versus salvage for D14-resiudal acute myeloid leukemia: A retrospective multi-center study.
     Leuk Res. 2022;119:106902.
     PubMed     Abstract available
     
     
     
140. OTHMAN T, Moskoff BN, Ho G, Tenold ME, et al
     Clinical experience with frontline Hyper-CVAD-based regimens, including Hyper-CVAD plus ponatinib, in patients with acute lymphoblastic leukemia treated at a comprehensive cancer center.
     Leuk Res. 2022;119:106885.
     PubMed     Abstract available
     
     
     
141. TATARIAN J, Byrd K, Male HJ, Lin TL, et al
     Central nervous system involvement in adult acute myeloid leukemia patients.
     Leuk Res. 2022;118:106882.
     PubMed    
     
     
     
142. HASHIMOTO H, Gungor D, Krickeberg N, Schmitt J, et al
     TH1 cytokines induce senescence in AML.
     Leuk Res. 2022;117:106842.
     PubMed     Abstract available
     
     
     May 2022
143. KIM K, Bazinet A, Loghavi S, Konopleva M, et al
     Major clinical response in a patient with leukemia cutis treated with the bromodomain inhibitor PLX51107 and azacitidine.
     Leuk Res. 2022;119:106884.
     PubMed    
     
     
     
144. GOSWAMI S, Chiang CL, Zapolnik K, Nunes J, et al
     ROR1 targeted immunoliposomal delivery of OSU-2S shows selective cytotoxicity in t(1;19)(q23;p13) translocated B-cell acute lymphoblastic leukemia.
     Leuk Res. 2022;118:106872.
     PubMed    
     
     
     
145. STEIDL C, Aroldi A, Mologni L, Crespiatico I, et al
     Validation of a new NGS-based myeloid panel in acute myeloid leukemia: A single-center experience.
     Leuk Res. 2022;118:106861.
     PubMed     Abstract available
     
     
     
146. TASHAKORI M, Wang W, Kadia TM, Daver NG, et al
     Differential characteristics of TP53 alterations in pure erythroid leukemia arising after exposure to cytotoxic therapy.
     Leuk Res. 2022;118:106860.
     PubMed     Abstract available
     
     
     
147. KIM T, Ahn JS, Son MH, Novitzky-Basso I, et al
     Genetic changes during leukemic transformation to secondary acute myeloid leukemia from myeloproliferative neoplasms.
     Leuk Res. 2022;118:106858.
     PubMed     Abstract available
     
     
     
148. KARBALIVAND M, Almada LL, Ansell SM, Fernandez-Zapico ME, et al
     MLL1 inhibition reduces IgM levels in Waldenstrom macroglobulinemia.
     Leuk Res. 2022;116:106841.
     PubMed     Abstract available
     
     
     
149. NORVILAS R, Batiuskaite R, Dirse V, Semaskeviciene R, et al
     Population-based targeted RNA sequencing reveals novel disease-related gene fusions in pediatric and adult T-ALL.
     Leuk Res. 2022;116:106825.
     PubMed     Abstract available
     
     
     April 2022
150. ARORA S, Zainaldin C, Bathini S, Gupta U, et al
     Tumor lysis syndrome and infectious complications during treatment with venetoclax combined with azacitidine or decitabine in patients with acute myeloid leukemia.
     Leuk Res. 2022;117:106844.
     PubMed     Abstract available
     
     
     
151. BAI H, Zhang Q, Zhang S, Wang J, et al
     Multiple cells of origin in common with various types of mouse N-Myc acute leukemia.
     Leuk Res. 2022;117:106843.
     PubMed     Abstract available
     
     
     March 2022
152. NGUYEN PC, Donati V, Vassili C, Grigg AP, et al
     Real-world tolerability of venetoclax-based maintenance therapy with azole antifungal prophylaxis for acute myeloid leukemia in remission.
     Leuk Res. 2022 Mar 27:106837. doi: 10.1016/j.leukres.2022.106837.
     PubMed    
     
     
     
153. SHEHATA AMF, Gohar SF, Muharram NM, Eldin SMK, et al
     LncRNA CCAT2 expression at diagnosis predicts imatinib response in chronic phase chronic myeloid leukemia patients.
     Leuk Res. 2022;116:106838.
     PubMed     Abstract available
     
     
     
154. TRIGUERO A, Xicoy B, Zamora L, Jimenez MJ, et al
     Response to azacitidine in patients with chronic myelomonocytic leukemia according to overlap myelodysplastic/myeloproliferative neoplasms criteria.
     Leuk Res. 2022;116:106836.
     PubMed     Abstract available
     
     
     
155. JELLOUL FZ, Yang R, Garces S, Kanagal-Shamanna R, et al
     Landscape of NOTCH1 mutations and co-occurring biomarker alterations in chronic lymphocytic leukemia.
     Leuk Res. 2022;116:106827.
     PubMed     Abstract available
     
     
     
156. BHREATHNACH U, Doherty D, Murphy K, Flynn CM, et al
     Monitoring KAT6A-CREBBP measurable residual disease in t(8;16) therapy-related acute myeloid leukemia.
     Leuk Res. 2022;116:106823.
     PubMed    
     
     
     
157. KAMATH-LOEB AS, Shen JC, Schmitt MW, Kohrn BF, et al
     Accurate detection of subclonal variants in paired diagnosis-relapse acute myeloid leukemia samples by next generation Duplex Sequencing.
     Leuk Res. 2022;115:106822.
     PubMed     Abstract available
     
     
     
158. HERNANDEZ-BOLUDA JC, Martinez-Cuadron D, Pereira A, Rodriguez-Veiga R, et al
     Acute leukemia arising from myeloproliferative or myelodysplastic/myeloproliferative neoplasms: A series of 372 patients from the PETHEMA AML registry.
     Leuk Res. 2022;115:106821.
     PubMed     Abstract available
     
     
     
159. WANG X, Bajpai AK, Gu Q, Centeno A, et al
     A systems genetics approach delineates the role of Bcl2 in leukemia pathogenesis.
     Leuk Res. 2022;114:106804.
     PubMed     Abstract available
     
     
     February 2022
160. DE BELLIS E, Imbergamo S, Candoni A, Lico A, et al
     Corrigendum to "Venetoclax in combination with hypomethylating agents in previously untreated patients with acute myeloid leukemia ineligible for intensive treatment: a real-life multicenter experience" [Leukemia Res. 114 (March 2022) 106803].
     Leuk Res. 2022 Feb 23:106811. doi: 10.1016/j.leukres.2022.106811.
     PubMed    
     
     
     
161. ROSTAMI M, Kharajo RS, Parsa-Kondelaji M, Ayatollahi H, et al
     Altered expression of NEAT1 variants and P53, PTEN, and BCL-2 genes in patients with acute myeloid leukemia.
     Leuk Res. 2022;115:106807.
     PubMed     Abstract available
     
     
     
162. NUHOGLU KANTARCI E, Eskazan AE
     Gilteritinib in the management of acute myeloid leukemia: Current evidence and future directions.
     Leuk Res. 2022;114:106808.
     PubMed     Abstract available
     
     
     
163. DE BELLIS E, Imbergamo S, Candoni A, Lico A, et al
     Venetoclax in combination with hypomethylating agents in previously untreated patients with acute myeloid leukemia ineligible for intensive treatment: a real-life multicenter experience.
     Leuk Res. 2022;114:106803.
     PubMed     Abstract available
     
     
     
164. KUSNE Y, Xie Z, Patnaik MM
     Clonal hematopoiesis: Molecular and clinical implications.
     Leuk Res. 2022;113:106787.
     PubMed     Abstract available
     
     
     
165. CHORNENKI NLJ, Siegal DM, Qamar K, Woolgar S, et al
     Characterizing Frailty In Myeloproliferative Neoplasms: results from the ORCHID study.
     Leuk Res. 2022;113:106788.
     PubMed    
     
     
     January 2022
166. PARK H, Kang S, Kim I, Kim S, et al
     The association of genetic alterations with response rate in newly diagnosed chronic myeloid leukemia patients.
     Leuk Res. 2022;114:106791.
     PubMed     Abstract available
     
     
     
167. THOMAS JW, Jamy O, Shah MV, Vachhani P, et al
     Risk of mortality and second malignancies in primary myelofibrosis before and after ruxolitinib approval.
     Leuk Res. 2022;112:106770.
     PubMed     Abstract available
     
     
     
168. SORIGUE M, Arenillas L, Xicoy B, Andrade-Campos M, et al
     Monocyte subset distribution in myeloproliferative and myelodysplastic/myeloproliferative neoplasms with monocytosis.
     Leuk Res. 2022;112:106771.
     PubMed    
     
     
     
169. ALAYED K, Meyerson HJ
     Decreased CD177(pos) neutrophils in myeloid neoplasms is associated with NPM1, RUNX1, TET2, and U2AF1 S34F mutations.
     Leuk Res. 2022;112:106752.
     PubMed     Abstract available
     
     
     
170. PARKER C, Ayton D, Zomer E, Liew D, et al
     Do patients with haematological malignancies suffer financial burden? A cross-sectional study of patients seeking care through a publicly funded healthcare system.
     Leuk Res. 2022;112:106748.
     PubMed     Abstract available
     
     
     December 2021
171. SHERBAN A, Raanani P, Gurion R, Wolach O, et al
     Maintenance therapy with hypomethylating agents for patients with acute myeloid leukemia in first remission not eligible for allogeneic hematopoietic cell transplantation: A systematic review and meta-analysis.
     Leuk Res. 2021;113:106773.
     PubMed     Abstract available
     
     
     
172. WEBSTER JA, Robinson TM, Blackford AL, Warlick E, et al
     A randomized, phase II trial of adjuvant immunotherapy with durable TKI-free survival in patients with chronic phase CML.
     Leuk Res. 2021;111:106737.
     PubMed     Abstract available
     
     
     
173. GAJZER D, Logothetis CN, Sallman DA, Calon G, et al
     MYC overexpression is associated with an early disease progression from MDS to AML.
     Leuk Res. 2021;111:106733.
     PubMed     Abstract available
     
     
     
174. OBENG-KUSI M, MacDonald K, van Lierde MA, Lee CS, et al
     No margin for non-adherence: Probabilistic kaplan-meier modeling of imatinib non-adherence and treatment response in CML (ADAGIO study).
     Leuk Res. 2021;111:106734.
     PubMed     Abstract available
     
     
     
175. KOTA V, Brummendorf TH, Gambacorti-Passerini C, Lipton JH, et al
     Efficacy and safety following bosutinib dose reduction in patients with Philadelphia chromosomepositive leukemias.
     Leuk Res. 2021;111:106690.
     PubMed     Abstract available
     
     
     
176. BAYRAK AG, Daglar Aday A, Yavuz AS, Nalcaci M, et al
     Overview of clinical and genetic features of CML patients with variant Philadelphia translocations involving chromosome 7: A case series.
     Leuk Res. 2021;111:106725.
     PubMed     Abstract available
     
     
     
177. MCBRIDE A, Daniel S, Driessen MT, Szende A, et al
     Assessment of rituximab-abbs, a biosimilar, and rituximab outcomes in patients with CLL or NHL: A real-world UK study.
     Leuk Res. 2021;111:106671.
     PubMed     Abstract available
     
     
     
178. BORSKY M, Hrabcakova V, Novotna J, Brychtova Y, et al
     Rituximab induces rapid blood repopulation by CLL cells mediated through their release from immune niches and complement exhaustion.
     Leuk Res. 2021;111:106684.
     PubMed     Abstract available
     
     
     November 2021
179. KAIVERS J, Peters J, Rautenberg C, Schroeder T, et al
     The WHO 2016 diagnostic criteria for Acute Myeloid leukemia with myelodysplasia related changes (AML-MRC) produce a very heterogeneous entity: A retrospective analysis of the FAB subtype RAEB-T.
     Leuk Res. 2021;112:106757.
     PubMed     Abstract available
     
     
     
180. PERMIKIN Z, Popov A, Verzhbitskaya T, Riger T, et al
     Lineage switch to acute myeloid leukemia during induction chemotherapy for early T-cell precursor acute lymphoblastic leukemia with the translocation t(6;11)(q27;q23)/KMT2A-AFDN: A case report.
     Leuk Res. 2021;112:106758.
     PubMed    
     
     
     
181. SREEDHARANUNNI S, Jamwal M, Balakrishnan A, Aravindan AV, et al
     Chronic eosinophilic leukemia with recurrent STAT5B N642H mutation-An entity with features of myelodysplastic syndrome/ myeloproliferative neoplasm overlap.
     Leuk Res. 2021;112:106753.
     PubMed    
     
     
     
182. CIROVIC A, Cirovic A
     Iron deficiency as promoter of heavy metals-induced acute myeloid leukemia.
     Leuk Res. 2021;112:106755.
     PubMed     Abstract available
     
     
     
183. NORSKOV KH, Fridthjof K, Kampmann P, Dunweber A, et al
     A national Danish proof of concept on feasibility and safety of home -based intensive chemotherapy in patients with acute myeloid leukemia.
     Leuk Res. 2021;112:106756.
     PubMed     Abstract available
     
     
     
184. KEE KM, Kim SH, Yang SY, Shin JU, et al
     Comparison of 3-month cytogenetic and molecular assays for early assessment of long-term clinical impact after BCR-ABL1 tyrosine kinase inhibitor treatment in chronic myeloid leukemia.
     Leuk Res. 2021;112:106754.
     PubMed     Abstract available
     
     
     
185. MIRFAKHRAIE R, Noorazar L, Mohammadian M, Hajifathali A, et al
     Treatment Failure in Acute Myeloid Leukemia: Focus on the Role of Extracellular Vesicles.
     Leuk Res. 2021;112:106751.
     PubMed     Abstract available
     
     
     
186. LIESVELD JL, Baran A, Azadniv M, Misch H, et al
     A phase II study of sequential decitabine and rapamycin in acute myelogenous leukemia.
     Leuk Res. 2021;112:106749.
     PubMed     Abstract available
     
     
     
187. GALASSI L, Colasante C, Bettelli F, Gilioli A, et al
     Pre-existing cytopenia heralding de novo acute myeloid leukemia: Uncommon presentation of NPM1-mutated AML in a single-center study.
     Leuk Res. 2021;111:106747.
     PubMed    
     
     
     
188. HUSELTON E, Rettig MP, Campbell K, Cashen AF, et al
     Combination of dociparstat sodium (DSTAT), a CXCL12/CXCR4 inhibitor, with azacitidine for the treatment of hypomethylating agent refractory AML and MDS.
     Leuk Res. 2021;110:106713.
     PubMed     Abstract available
     
     
     
189. WONG R, Nguyen A, Wang X, Chong L, et al
     Improved resolution of phenotypic subsets in human T-ALL by incorporation of RNA-seq based developmental profiling.
     Leuk Res. 2021;110:106712.
     PubMed    
     
     
     
190. AN L, Li X, Yang J
     MicroRNA-211 attenuates cell proliferation in T-cell lymphoblastic lymphoma through targeting TCF12.
     Leuk Res. 2021;110:106653.
     PubMed     Abstract available
     
     
     October 2021
191. LUGER SM, Wang VX, Rowe JM, Litzow MR, et al
     Tipifarnib as maintenance therapy did not improve disease-free survival in patients with acute myelogenous leukemia at high risk of relapse: Results of the phase III randomized E2902 trial.
     Leuk Res. 2021;111:106736.
     PubMed     Abstract available
     
     
     
192. CHOW S, Tang K, Al-Abri M, Hall V, et al
     RUNX1 mutations correlate with response to venetoclax combination therapies in relapsed/refractory acute myeloid leukemia.
     Leuk Res. 2021;111:106735.
     PubMed    
     
     
     
193. KANNAN KK, Vellanki P, Isom S, Tawfik B, et al
     Re-induction therapy in adult patients with acute myeloid leukemia with
     Leuk Res. 2021;111:106731.
     PubMed    
     
     
     
194. BAGHAEI VAJI F, Boroumand Nasr A, Rezvani A, Ayatollahi H, et al
     Prognostic significance of ATM mutations in chronic lymphocytic leukemia: A meta-analysis.
     Leuk Res. 2021;111:106729.
     PubMed     Abstract available
     
     
     
195. KALEKA G, Schiller G
     Immunotherapy for Acute Myeloid Leukemia: Allogeneic hematopoietic cell transplantation is here to stay.
     Leuk Res. 2021;112:106732.
     PubMed     Abstract available
     
     
     
196. PADMAKUMAR D, Chandraprabha VR, Gopinath P, Vimala Devi ART, et al
     A concise review on the molecular genetics of acute myeloid leukemia.
     Leuk Res. 2021;111:106727.
     PubMed     Abstract available
     
     
     
197. PARK H, Kim I, Kim HJ, Shin DY, et al
     Ultra-deep sequencing mutation analysis of the BCR/ABL1 kinase domain in newly diagnosed chronic myeloid leukemia patients.
     Leuk Res. 2021;111:106728.
     PubMed     Abstract available
     
     
     
198. MARTINEZ-VERBO L, Estrada N, Cabezon M, Palomo L, et al
     Mutational profile and relative telomere length in Chronic Myelomonocytic Leukemia subgroups according to the 2016 World Health Organization classification.
     Leuk Res. 2021;111:106726.
     PubMed    
     
     
     
199. LIM K, Thompson-Peach C, Thomas D
     Neonatal heel prick mass spectrometry identifies metabolic predictors of AML latency.
     Leuk Res. 2021;109:106644.
     PubMed     Abstract available
     
     
     September 2021
200. GOKCEN S, Bagriacik EU, Kayhan H, Yagci M, et al
     Immunomolecular evaluation of dihydroartemisinin effects on apoptosis in chronic lymphocytic leukemia cell lines.
     Leuk Res. 2021;110:106702.
     PubMed     Abstract available
     
     
     
201. ESFANDBOD M, Enshaei M, Monzavi SM, Kabootari M, et al
     Radiation-Free myeloablative allogeneic hematopoietic stem cell transplantation for adult acute lymphoblastic leukemia: A comparison of outcomes between patients with and without central nervous system involvement.
     Leuk Res. 2021;111:106703.
     PubMed     Abstract available
     
     
     
202. CARRAWAY HE, Sawalha Y, Gojo I, Lee MJ, et al
     Phase 1 study of the histone deacetylase inhibitor entinostat plus clofarabine for poor-risk Philadelphia chromosome-negative (newly diagnosed older adults or adults with relapsed refractory disease) acute lymphoblastic leukemia or biphenotypic leukem
     Leuk Res. 2021;110:106707.
     PubMed     Abstract available
     
     
     
203. DU X, Liu H, Yang C, Shi X, et al
     LncRNA landscape analysis identified LncRNA LEF-AS1 as an oncogene that upregulates LEF1 and promotes survival in chronic lymphocytic leukemia.
     Leuk Res. 2021;110:106706.
     PubMed     Abstract available
     
     
     
204. ALVAREZ N, Rodriguez-Garcia A, Morales ML, Gutierrez M, et al
     Clonal hematopoiesis-defining mutations have no impact on the development of thrombosis in a cohort of patients with myeloid pathology.
     Leuk Res. 2021;108:106613.
     PubMed    
     
     
     
205. ALEISSA MM, Alshehri BS, Gonzalez-Bocco IH, McDonnell AM, et al
     Triazole antifungal use for prophylaxis and treatment of invasive fungal diseases for patients receiving gilteritinib.
     Leuk Res. 2021;108:106610.
     PubMed     Abstract available
     
     
     
206. LINCH DC, Hills RK, Gilkes A, Burnett AK, et al
     Additional impact of mutational genotype on prognostic determination in resistant and relapsed acute myeloid leukaemia.
     Leuk Res. 2021;108:106553.
     PubMed     Abstract available
     
     
     August 2021
207. YU J, Du Y, Jalil A, Ahmed Z, et al
     Mutational profiling of myeloid neoplasms associated genes may aid the diagnosis of acute myeloid leukemia with myelodysplasia-related changes.
     Leuk Res. 2021;110:106701.
     PubMed     Abstract available
     
     
     
208. ABRAMENKO I, Bilous N, Chumak A, Kryachok I, et al
     The signs of negative selection in IGHV framework regions are associated with worse overall survival of chronic lymphocytic leukemia patients.
     Leuk Res. 2021;110:106686.
     PubMed     Abstract available
     
     
     
209. DARASKEVICIUS J, Everatt V, Vaitekenaite V, Ringeleviciute U, et al
     Venetoclax in combination with low dose Cytarabine and Actinomycin D for primary refractory acute myeloid leukemia patients failing intensive chemotherapy.
     Leuk Res. 2021;111:106692.
     PubMed    
     
     
     
210. RAHIMI Z, Ghorbani Z, Motamed H, Jalilian N, et al
     Aberrant expression profile of miR-32, miR-98 and miR-374 in chronic lymphocytic leukemia.
     Leuk Res. 2021;111:106691.
     PubMed     Abstract available
     
     
     
211. YOUNG PE, Kanagal-Shamanna R, Hu S, Tang G, et al
     Chronic myeloid leukemia, BCR-ABL1-positive, carrying NPM1 mutation - First case series from a single institution.
     Leuk Res. 2021;111:106685.
     PubMed    
     
     
     
212. GOWIN K, Skerget S, Keats JJ, Mikhael J, et al
     Plasma cell leukemia: A review of the molecular classification, diagnosis, and evidenced-based treatment.
     Leuk Res. 2021;111:106687.
     PubMed     Abstract available
     
     
     
213. GUPTA SK, Bakhshi S, Kamal VK, Gupta R, et al
     Proposal and clinical application of molecular genetic risk scoring system, "MRplus", for BCR-ABL1 negative pediatric B-cell acute lymphoblastic leukemia- report from a single centre.
     Leuk Res. 2021;111:106683.
     PubMed     Abstract available
     
     
     July 2021
214. PLESA A, Roumier C, Gutrin J, Larcher MV, et al
     Measurable residual disease including AML leukemia stem cell flow evaluation of CPX-351 therapy by multi-parameter flow cytometry.
     Leuk Res. 2021;111:106673.
     PubMed    
     
     
     
215. MA CE, Ghosh S, Leyshon C, Blosser N, et al
     Clinical outcome of chronic myeloid leukemia patients who switch from first-line therapy with a second generation tyrosine kinase inhibitor to an alternative TKI.
     Leuk Res. 2021;111:106674.
     PubMed     Abstract available
     
     
     
216. ALSHEMMARI SH, Hamdah A, Pandita R, Kunhikrishnan A, et al
     Chronic lymphocytic leukemia in a young population.
     Leuk Res. 2021;110:106668.
     PubMed     Abstract available
     
     
     
217. SILVA WF, Silverio A, Duarte BKL, Aguiar TF, et al
     Philadelphia-positive B-lymphoblastic leukemia in a middle-income country - A real-world multicenter cohort.
     Leuk Res. 2021;110:106666.
     PubMed     Abstract available
     
     
     
218. HARRIS RA, Stevens JM, Pickering DL, Althof PA, et al
     Frequency, variations, and prognostic implications of chromosome 14q32 deletions in chronic lymphocytic leukemia.
     Leuk Res. 2021;110:106665.
     PubMed     Abstract available
     
     
     
219. SMITH MR, Cronin JF, Weiss RF
     Alternative strategies for optimizing treatment of chronic lymphocytic leukemia with complex clonal architecture.
     Leuk Res. 2021;110:106663.
     PubMed     Abstract available
     
     
     
220. DEMINA I, Zerkalenkova E, Zhogov V, Lagoyko S, et al
     The use of additional immunophenotypic criteria for the differential diagnosis of Burkitt lymphoma/leukemia: An exemplary case report.
     Leuk Res. 2021;110:106662.
     PubMed    
     
     
     
221. IBRAHIM M, Chen R, Vegel A, Panse K, et al
     Treatment of myeloid sarcoma without bone marrow involvement with gemtuzumab ozogamicin-containing regimen.
     Leuk Res. 2021;106:106583.
     PubMed    
     
     
     
222. GLASS JL, Derkach A, Hilden P, King A, et al
     Arsenic trioxide therapy predisposes to herpes zoster reactivation despite minimally myelosuppressive therapy.
     Leuk Res. 2021;106:106569.
     PubMed     Abstract available
     
     
     June 2021
223. KONDYLI M, Tremblay DE, Rezgui A, Serfaty SA, et al
     Human Leucocyte Antigen alleles associated with asparaginase hypersensitivity in childhood Acute Lymphoblastic Leukemia patients treated with Pegylated asparaginase within Dana Farber Cancer Institute treatment protocols.
     Leuk Res. 2021;109:106650.
     PubMed    
     
     
     
224. CHENG L, Zeng S, Yan D, Tu L, et al
     Cytarabine and EIP co-administration synergistically reduces viability of acute lymphoblastic leukemia cells with high ERG expression.
     Leuk Res. 2021;109:106649.
     PubMed     Abstract available
     
     
     
225. ZHANG Y, Feng S
     The impact of tyrosine kinase inhibitors on allogeneic hematopoietic stem cell transplantation for adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia.
     Leuk Res. 2021;109:106647.
     PubMed     Abstract available
     
     
     
226. ZAMANI A, Fattahi Dolatabadi N, Houshmand M, Nabavizadeh N, et al
     miR-324-3p and miR-508-5p expression levels could serve as potential diagnostic and multidrug-resistant biomarkers in childhood acute lymphoblastic leukemia.
     Leuk Res. 2021;109:106643.
     PubMed     Abstract available
     
     
     
227. GUPTA SK, Singh P, Chhabra R, Verma M, et al
     Novel pharmacological approach for the prevention of multidrug resistance (MDR) in a human leukemia cell line.
     Leuk Res. 2021;109:106641.
     PubMed     Abstract available
     
     
     
228. HUNTER AM, Al Ali N, Mai A, Shah S, et al
     Leukocytosis is associated with end organ damage and mortality in chronic myelomonocytic leukemia and can be mitigated by cytoreductive therapy.
     Leuk Res. 2021;109:106640.
     PubMed    
     
     
     
229. GENESCA E, Morgades M, Gonzalez-Gil C, Fuster-Tormo F, et al
     Adverse prognostic impact of complex karyotype (>/=3 cytogenetic alterations) in adult T-cell acute lymphoblastic leukemia (T-ALL).
     Leuk Res. 2021;109:106612.
     PubMed     Abstract available
     
     
     
230. SONG J, Shang B, Pei Y, Shi M, et al
     A higher percentage of leukemic blasts with vacuoles predicts unfavorable outcomes in patients with acute myeloid leukemia.
     Leuk Res. 2021;109:106638.
     PubMed     Abstract available
     
     
     
231. ISHDORJ G, Nugent Z, Squires M, Kost S, et al
     Rapid improvement in symptoms and physical function following ibrutinib initiation in chronic lymphocytic leukemia and the associated changes in plasma cytokines.
     Leuk Res. 2021;109:106628.
     PubMed     Abstract available
     
     
     
232. CHANDRA SEKARAN U, Grove CS
     Prognostic factors and their importance in relapsed and refractory AML: Comments on "Additional impact of mutational genotype on prognostic determination in resistant and relapsed acute myeloid leukaemia" by Linch et al.
     Leuk Res. 2021;105:106572.
     PubMed    
     
     
     
233. MIYAUCHI J, Kawaguchi H
     The in vitro effects of hepatoblastoma cells on the growth and differentiation of blasts in transient abnormal myelopoiesis associated with Down syndrome.
     Leuk Res. 2021;105:106570.
     PubMed     Abstract available
     
     
     May 2021
234. YASUDA S, Najima Y, Konishi T, Yamada Y, et al
     Outcome of allogeneic hematopoietic stem cell transplantation for T-cell lymphoblastic leukemia/lymphoma: A single-center study.
     Leuk Res. 2021;108:106627.
     PubMed     Abstract available
     
     
     
235. TANG Z, Kanagal-Shamanna R, Tang G, Patel K, et al
     Analytical and clinical performance of chromosomal microarrays compared with FISH panel and conventional karyotyping in patients with chronic lymphocytic leukemia.
     Leuk Res. 2021;108:106616.
     PubMed     Abstract available
     
     
     
236. FIEGLE E, Crysandt M, Bouillon AS, Silling G, et al
     Successful allogeneic stem cell transplantation of a patient with Werner syndrome and acute myeloid leukemia.
     Leuk Res. 2021 May 5:106609. doi: 10.1016/j.leukres.2021.106609.
     PubMed    
     
     
     
237. ALI H, Salhotra A, Stein AS, Nakamura R, et al
     Efficacy of blinatumomab for MRD relapse in ALL post allogenic HCT.
     Leuk Res. 2021;104:106579.
     PubMed    
     
     
     
238. ETIENNE G, Rea D, Coiteux V, Guerci-Bresler A, et al
     Ponatinib long-term follow-up of efficacy and safety in CP-CML patients in real world settings in France: The POST-PACE study.
     Leuk Res. 2021;104:106541.
     PubMed    
     
     
     April 2021
239. HOCH REE, Coser VM, Santos IS, de Souza APD, et al
     Lymphoid markers predict prognosis of pediatric and adolescent acute myeloid leukemia.
     Leuk Res. 2021;107:106603.
     PubMed     Abstract available
     
     
     
240. HELALY NA, Esheba NE, Ammo DEA, Elwan NM, et al
     High Bax/Bcl-2 ratio is associated with good prognosis and better survival in patients with B cell chronic lymphocytic leukemia.
     Leuk Res. 2021;107:106604.
     PubMed     Abstract available
     
     
     
241. SPEROTTO A, Gottardi M, Candoni A, Toffoletti E, et al
     WT1 - Gene expression driven pre-emptive treatment with decitabine for molecular relapse of acute myeloid leukemia after allogeneic stem cell transplant.
     Leuk Res. 2021;108:106587.
     PubMed    
     
     
     
242. VACHHANI P, Baron J, Freyer CW, Miller A, et al
     A phase 2 trial of single low doses of rasburicase for treatment of hyperuricemia in adult patients with acute leukemia.
     Leuk Res. 2021;107:106588.
     PubMed     Abstract available
     
     
     
243. CHEN P, Redd L, Schmidt Y, Koduru P, et al
     MYC protein expression does not correlate with MYC abnormalities detected by FISH but predicts an unfavorable prognosis in de novo acute myeloid leukemia.
     Leuk Res. 2021;106:106584.
     PubMed     Abstract available
     
     
     
244. PETRICK L, Imani P, Perttula K, Yano Y, et al
     Untargeted metabolomics of newborn dried blood spots reveals sex-specific associations with pediatric acute myeloid leukemia.
     Leuk Res. 2021;106:106585.
     PubMed     Abstract available
     
     
     
245. GARCIA JS, Swords RT, Roboz GJ, Jacoby MA, et al
     Corrigendum to "A systematic review of higher-risk myelodysplastic syndromes clinical trials to determine the benchmark of azacitidine and explore alternative endpoints for overall survival" [Leukemia Res. 104 March (2021)].
     Leuk Res. 2021 Apr 22:106581. doi: 10.1016/j.leukres.2021.106581.
     PubMed    
     
     
     
246. KRISTENSEN D, Nielsen LB, Roug AS, Kristensen TC, et al
     The prognostic impact of anthropometrics in acute myeloid leukemia treated with intensive chemotherapy - A Danish nationwide cohort study.
     Leuk Res. 2021;106:106567.
     PubMed    
     
     
     
247. KIM YJ, Jung SH, Hur EH, Choi EJ, et al
     Clinical implications of copy number alteration detection using panel-based next-generation sequencing data in myelodysplastic syndrome.
     Leuk Res. 2021;103:106540.
     PubMed     Abstract available
     
     
     March 2021
248. PARK S, Choi EJ, Lee H, Jo DY, et al
     Treatment-free remission of chronic myeloid leukemia in real-world practice by the detection limit of MR4.3.
     Leuk Res. 2021;105:106578.
     PubMed     Abstract available
     
     
     
249. MUUS P, Langemeijer S, van Bijnen S, Blijlevens N, et al
     A phase I clinical trial to study the safety of treatment with tipifarnib combined with bortezomib in patients with advanced stages of myelodysplastic syndrome and oligoblastic acute myeloid leukemia.
     Leuk Res. 2021;105:106573.
     PubMed     Abstract available
     
     
     
250. ROBAK E, Jesionek-Kupnicka D, Iskierka-Jazdzewska E, Janus A, et al
     Cutaneous leukocytoclastic vasculitis at diagnosis of hairy cell leukemia successfully treated with vemurafenib and rituximab.
     Leuk Res. 2021;104:106571.
     PubMed    
     
     
     
251. MOHTY R, Massoud R, Chakhachiro Z, Mahfouz R, et al
     Risk adapted therapeutic strategy in newly diagnosed acute myeloid leukemia: Refining the outcomes of ELN 2017 intermediate-risk patients.
     Leuk Res. 2021;105:106568.
     PubMed     Abstract available
     
     
     
252. NI J, Hong J, Li Q, Zeng Q, et al
     Long non-coding RNA CRNDE suppressing cell proliferation is regulated by DNA methylation in chronic lymphocytic leukemia.
     Leuk Res. 2021;105:106564.
     PubMed     Abstract available
     
     
     
253. OZKAN T, Hekmatshoar Y, Karabay AZ, Koc A, et al
     Assessment of azithromycin as an anticancer agent for treatment of imatinib sensitive and resistant CML cells.
     Leuk Res. 2021;102:106523.
     PubMed     Abstract available
     
     

Thank you for your interest in scientific medicine.

AMEDEO Leukemia is free of charge.